BioLight Life Sciences (TASE:BOLT) announced successful results from its glaucoma insert, VS101, (Eye-D latanoprost) in a Phase 1/2a clinical trial, which demonstrated its ability to lower intraocular pressure (IOP) for a 12-week period, with a favorable safety profile.
The Eye-D latanoprost insert is designed to provide sustained IOP-lowering for patients who have difficulty taking their prescribed eye drops for the treatment of glaucoma on a continuous daily basis.
BioLight’s first-in-human study was designed to compare three doses of its Eye-D latanoprost inserts to once-daily latanoprost eye drops. The Phase 1/2a results comprise data from 77 glaucoma patients that were collected from 19 clinical centers across the U.S.
The data demonstrated that a single placement of the Eye-D latanoprost insert of one of the three doses provided the best sustained reduction in IOP throughout the 12 weeks follow up, with a positive safety profile.
Principal investigator, Dr. Howard Barnebey, said the Eye-D latanoprost insert has now successfully demonstrated effective intra-ocular pressure lowering for three months after subconjunctival placement of the insert in human eyes, and was well tolerated.
“This innovative insert presents a promising approach to improving therapeutic compliance, bypassing the issues of patients remembering to take medication as well as instilling it in their eyes,” he added.
BioLight CEO, Suzana Zilberberg, said the company intends to continue its discussions with potential strategic partners, aiming to advance the development and approval process for the Eye-D latanoprost insert, while, at the same time, promoting additional steps that will assist in optimizing the treatment for glaucoma patients.
“This novel technology and its first indication, have the potential of becoming an important advance in the treatment of glaucoma patients,” she added.
